These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3239704)

  • 21. Improving antiproliferative effect of the anticancer drug cytarabine on human promyelocytic leukemia cells by coating on Fe3O4@SiO2 nanoparticles.
    Shahabadi N; Falsafi M; Mansouri K
    Colloids Surf B Biointerfaces; 2016 May; 141():213-222. PubMed ID: 26852105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells.
    Leardi A; Caraglia M; Selleri C; Pepe S; Pizzi C; Notaro R; Fabbrocini A; De Lorenzo S; Musicò M; Abbruzzese A; Bianco AR; Tagliaferri P
    Br J Haematol; 1998 Aug; 102(3):746-52. PubMed ID: 9722302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (-)-Epigallocatechin-3-gallate enhances anti-tumor effect of cytosine arabinoside on HL-60 cells.
    Xu F; Zhen YS
    Acta Pharmacol Sin; 2003 Feb; 24(2):163-8. PubMed ID: 12546725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
    Grant S; Freemerman AJ; Birrer MJ; Martin HA; Turner AJ; Szabo E; Chelliah J; Jarvis WD
    Cell Growth Differ; 1996 May; 7(5):603-13. PubMed ID: 8732670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro activity of several cytostatic drugs against aerobic and anaerobic intestinal bacteria].
    Vetere A; Giuliano M; Pantosti A; Panichi G
    Boll Ist Sieroter Milan; 1984; 63(6):505-9. PubMed ID: 6534396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies.
    Dezza L; Cazzola M; Danova M; Carlo-Stella C; Bergamaschi G; Brugnatelli S; Invernizzi R; Mazzini G; Riccardi A; Ascari E
    Leukemia; 1989 Feb; 3(2):104-7. PubMed ID: 2911202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flow cytometric analysis of the cell cycle of the leukemic cell lines treated with etoposide and cytosine arabinoside.
    Ishiyama K; Satoh S; Igarashi Y; Kumagai H; Yahagi A; Sasaki H
    Tohoku J Exp Med; 1994 Oct; 174(2):95-107. PubMed ID: 7900157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine.
    Momparler RL; Bouffard DY; Momparler LF; Marquet J; Zittoun J; Marie JP; Zittoun R
    Int J Cancer; 1991 Oct; 49(4):573-6. PubMed ID: 1917159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonism of drugs used in leukaemia therapy to the killing of human lymphoblastoid cells by steroid.
    Gledhill RM; Norman MR
    Br J Cancer; 1981 Sep; 44(3):467-71. PubMed ID: 6945118
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of cytotoxic drugs on neutrophil phagocytosis in vitro and in patients with acute myelogenous leukaemia.
    Davies JE; Whittaker JA; Khurshid M
    Br J Haematol; 1976 Jan; 32(1):21-7. PubMed ID: 769820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
    Budman DR; Calabro A; Kreis W
    Leukemia; 2001 Oct; 15(10):1517-20. PubMed ID: 11587208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
    Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
    Minderman H; Zhou Y; O'Loughlin KL; Baer MR
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs.
    Cole PD; Smith AK; Kamen BA
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):111-6. PubMed ID: 12172974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
    Kristensen J; Nygren P; Liliemark J; Fridborg H; Killander A; Simonsson B; Oberg G; Larsson R
    Leukemia; 1994 Oct; 8(10):1712-7. PubMed ID: 7934168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line.
    Verschuur AC; Brinkman J; Van Gennip AH; Leen R; Vet RJ; Evers LM; Voûte PA; Van Kuilenburg AB
    Leuk Res; 2001 Oct; 25(10):891-900. PubMed ID: 11532523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines.
    Lishner M; Bar-Sef A; Elis A; Fabian I
    J Investig Med; 2001 Jul; 49(4):319-24. PubMed ID: 11478407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.